{"id":"W4233817719","doi":"10.1056/nejmoa1602773","title":"Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease","year":2016,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1806,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; University of Calgary; Robarts Clinical Trials; Western University","funders":"Janssen Research and Development; Merck Sharp and Dohme; UCB Pharma; Sun Pharma; Tillotts Pharma; Amgen; Seres Therapeutics; Celltrion; Genentech; Janssen Scientific Affairs; Celgene; Biogen; Gilead Sciences; Dr. Falk Pharma; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Ustekinumab; Medicine; Crohn's disease; Maintenance therapy; Interleukin 23; Monoclonal antibody; Monoclonal; Disease; Immunology; Interleukin; Internal medicine; Antibody; Cytokine; Chemotherapy; Adalimumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01067286993960359,"score_gpt":0.2590847257424746,"score_spread":0.248411855802871,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}